We are early in the process but there is a high level of interest from a number of parties.

This is consistent with our strategy to participate in the generic market for Pfizer products that become subject to generic competition.

There is a wait-and-see attitude on the part of many observers, ... But we believe there have been some bright spots.

Those deficiencies are noted, but at the same time, there is no mention about the Medicare discount cards that were introduced last year. These cards provide discounts between 30 and 40 percent or even more for uninsured patients.

The report focuses on prices paid by consumers without insurance and in doing so excludes manufacturer rebates or discounts.

An important component of the reorganization is the additional resources and more intense focus we're bringing to the U.S. market because of the size and critical importance of the U.S. to our business.

We think between what's in our current pipeline and what we hope is going to be on the market over the next few years, combined with the savings we are going to realize from our efficiency initiation, that we will meet our growth target for the longer term.

We've got a need to acquire products in the near term with all our patent expirations.